Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5127]

PALOMA-3 update, including OS data for HR positive HER2 negative breast cancer

Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA

PALOMA-3 update, including OS data for HR positive HER2 negative breast cancer ( Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA )

Results from the PALOMA-3 trial for advanced breast cancer

Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA

Results from the PALOMA-3 trial for advanced breast cancer ( Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA )

Societal indicators of lung cancer screening behaviours

Prof Jean-François Morère - Hôpital Paul Brousse, Villejuif, France

Societal indicators of lung cancer screening behaviours ( Prof Jean-François Morère - Hôpital Paul Brousse, Villejuif, France )

Rare EGFR mutations in lung adenocarcinoma

Prof Nicolas Girard - Institut Curie, Paris, France

Rare EGFR mutations in lung adenocarcinoma ( Prof Nicolas Girard - Institut Curie, Paris, France )

New therapeutic options in advanced and metastatic breast cancer

Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal

New therapeutic options in advanced and metastatic breast cancer ( Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal )

Immunological monitoring of patients receiving immunotherapy

Prof Jaques van Dongen - Leiden University, Netherlands

Immunological monitoring of patients receiving immunotherapy ( Prof Jaques van Dongen - Leiden University, Netherlands )

Novel therapies for paediatric B-ALL

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

Novel therapies for paediatric B-ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )

Can we reduce the intensity of frontline therapy?

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

Can we reduce the intensity of frontline therapy? ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )

Latest concepts in the diagnosis of genetic ALL subtypes

Dr Charles Mullighan - St Jude Children's Research Hospital, Memphis, USA

Latest concepts in the diagnosis of genetic ALL subtypes ( Dr Charles Mullighan - St Jude Children's Research Hospital, Memphis, USA )

In vitro diagnostic models for ALL: what can we learn on actionable targets?

Dr Beat Bornhauser - Senior Scientist, University of Zurich, Zurich, Switzerland

In vitro diagnostic models for ALL: what can we learn on actionable targets? ( Dr Beat Bornhauser - Senior Scientist, University of Zurich, Zurich, Switzerland )

For HSCT in Ph-positive ALL

Prof Oliver Ottmann - Cardiff University, Cardiff, UK

For HSCT in Ph-positive ALL ( Prof Oliver Ottmann - Cardiff University, Cardiff, UK )

Bispecific T-cell engaging therapy for adult ALL

Prof Max Topp - University of Würzburg, Würzburg, Germany

Bispecific T-cell engaging therapy for adult ALL ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

More from ecancer